Literature DB >> 18812621

Isolation of human monoclonal antibodies by mammalian cell display.

Roger R Beerli1, Monika Bauer, Regula B Buser, Myriam Gwerder, Simone Muntwiler, Patrik Maurer, Philippe Saudan, Martin F Bachmann.   

Abstract

Due to their low immunogenicity in patients, humanized or fully human mAbs are becoming increasingly important for the treatment of a growing number of diseases, including cancer, infections, and immune disorders. Here, we describe a technology allowing for the rapid isolation of fully human mAbs. In contrast to previously described methods, B cells specific for an antigen of interest are directly isolated from peripheral blood mononuclear cells (PBMC) of human donors. Recombinant, antigen-specific single-chain Fv (scFv) libraries are generated from this pool of B cells and screened by mammalian cell surface display by using a Sindbis virus expression system. This method allows isolating antigen-specific antibodies by a single round of FACS. The variable regions (VRs) of the heavy chains (HCs) and light chains (LCs) are isolated from positive clones and recombinant fully human antibodies produced as whole IgG or Fab fragments. In this manner, several hypermutated high-affinity antibodies binding the Qbeta virus like particle (VLP), a model viral antigen, as well as antibodies specific for nicotine were isolated. All antibodies showed high expression levels in cell culture. The human nicotine-specific mAbs were validated preclinically in a mouse model. Thus, the technology presented here allows for rapid isolation of high-affinity, fully human antibodies with therapeutic potential from human volunteers.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18812621      PMCID: PMC2567231          DOI: 10.1073/pnas.0805942105

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  36 in total

1.  Passive immunization against nicotine prevents nicotine alleviation of nicotine abstinence syndrome.

Authors:  D H Malin; J R Lake; A Lin; M Saldaña; L Balch; M L Irvin; H Chandrasekara; C L Alvarado; Y Hieda; D E Keyler; P R Pentel; S Ennifar; L E Basham; R Naso; A Fattom
Journal:  Pharmacol Biochem Behav       Date:  2001-01       Impact factor: 3.533

2.  Rapid response of marginal zone B cells to viral particles.

Authors:  Dominique Gatto; Christiane Ruedl; Bernhard Odermatt; Martin F Bachmann
Journal:  J Immunol       Date:  2004-10-01       Impact factor: 5.422

3.  Measurements of the true affinity constant in solution of antigen-antibody complexes by enzyme-linked immunosorbent assay.

Authors:  B Friguet; A F Chaffotte; L Djavadi-Ohaniance; M E Goldberg
Journal:  J Immunol Methods       Date:  1985-03-18       Impact factor: 2.303

4.  Protein displays of the human immunoglobulin heavy, kappa and lambda variable and joining regions.

Authors:  D Scaviner; V Barbié; M Ruiz; M P Lefranc
Journal:  Exp Clin Immunogenet       Date:  1999

5.  Generation of recombinant human monoclonal antibodies to rotavirus from single antigen-specific B cells selected with fluorescent virus-like particles.

Authors:  Jörn Hendrik Weitkamp; Nicole Kallewaard; Koichi Kusuhara; Dino Feigelstock; Ninguo Feng; Harry B Greenberg; James E Crowe
Journal:  J Immunol Methods       Date:  2003-04-01       Impact factor: 2.303

6.  Making antibody fragments using phage display libraries.

Authors:  T Clackson; H R Hoogenboom; A D Griffiths; G Winter
Journal:  Nature       Date:  1991-08-15       Impact factor: 49.962

7.  Monoclonal antibody therapeutic trials in seven patients with T-cell lymphoma.

Authors:  R A Miller; A R Oseroff; P T Stratte; R Levy
Journal:  Blood       Date:  1983-11       Impact factor: 22.113

8.  Nicotine and carbamylcholine binding to nicotinic acetylcholine receptors as studied in AChBP crystal structures.

Authors:  Patrick H N Celie; Sarah E van Rossum-Fikkert; Willem J van Dijk; Katjusa Brejc; August B Smit; Titia K Sixma
Journal:  Neuron       Date:  2004-03-25       Impact factor: 17.173

9.  Reshaping human antibodies for therapy.

Authors:  L Riechmann; M Clark; H Waldmann; G Winter
Journal:  Nature       Date:  1988-03-24       Impact factor: 49.962

10.  An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus.

Authors:  Elisabetta Traggiai; Stephan Becker; Kanta Subbarao; Larissa Kolesnikova; Yasushi Uematsu; Maria Rita Gismondo; Brian R Murphy; Rino Rappuoli; Antonio Lanzavecchia
Journal:  Nat Med       Date:  2004-07-11       Impact factor: 53.440

View more
  60 in total

1.  Development of a novel mammalian cell surface antibody display platform.

Authors:  Chen Zhou; Frederick W Jacobsen; Ling Cai; Qing Chen; Weyen David Shen
Journal:  MAbs       Date:  2010-09-01       Impact factor: 5.857

2.  Spatially addressed combinatorial protein libraries for recombinant antibody discovery and optimization.

Authors:  Hongyuan Mao; James J Graziano; Tyson M A Chase; Cornelia A Bentley; Omar A Bazirgan; Neil P Reddy; Byeong Doo Song; Vaughn V Smider
Journal:  Nat Biotechnol       Date:  2010-10-24       Impact factor: 54.908

Review 3.  Mining human antibody repertoires.

Authors:  Roger R Beerli; Christoph Rader
Journal:  MAbs       Date:  2010-07-01       Impact factor: 5.857

4.  Tentative identification of sex-specific antibodies and their application for screening bovine sperm proteins for sex-specificity.

Authors:  Wu-Cai Yang; Lei Sang; Yao Xiao; Hua-Lin Zhang; Ke-Qiong Tang; Li-Guo Yang
Journal:  Mol Biol Rep       Date:  2013-11-12       Impact factor: 2.316

Review 5.  Development of vaccines to treat opioid use disorders and reduce incidence of overdose.

Authors:  Marco Pravetoni; Sandra D Comer
Journal:  Neuropharmacology       Date:  2019-06-04       Impact factor: 5.250

6.  Magnetic Bead-Immobilized Mammalian Cells Are Effective Targets to Enrich Ligand-Displaying Yeast.

Authors:  Patrick S Lown; Benjamin J Hackel
Journal:  ACS Comb Sci       Date:  2020-04-27       Impact factor: 3.784

7.  Mining the human autoantibody repertoire: isolation of potent IL17A-neutralizing monoclonal antibodies from a patient with thymoma.

Authors:  Roger R Beerli; Monika Bauer; Andrea Fritzer; Lindsey B Rosen; Regula B Buser; Markus Hanner; Melanie Maudrich; Mario Nebenfuehr; Jorge Alejandro Sepulveda Toepfer; Susanne Mangold; Anton Bauer; Steven M Holland; Sarah K Browne; Andreas Meinke
Journal:  MAbs       Date:  2014       Impact factor: 5.857

8.  Reprogramming Exosomes as Nanoscale Controllers of Cellular Immunity.

Authors:  Qinqin Cheng; Xiaojing Shi; Menglu Han; Goar Smbatyan; Heinz-Josef Lenz; Yong Zhang
Journal:  J Am Chem Soc       Date:  2018-11-19       Impact factor: 15.419

9.  Prophylactic and therapeutic activity of fully human monoclonal antibodies directed against influenza A M2 protein.

Authors:  Roger R Beerli; Monika Bauer; Nicole Schmitz; Regula B Buser; Myriam Gwerder; Simone Muntwiler; Wolfgang A Renner; Philippe Saudan; Martin F Bachmann
Journal:  Virol J       Date:  2009-12-21       Impact factor: 4.099

10.  Lymphocyte display: a novel antibody selection platform based on T cell activation.

Authors:  Vanesa Alonso-Camino; David Sánchez-Martín; Marta Compte; Laura Sanz; Luis Alvarez-Vallina
Journal:  PLoS One       Date:  2009-09-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.